Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Yahoo! Finance
See our latest analysis for Palvella Therapeutics. The latest move takes Palvella's share price to $99.73, capping a powerful 90 day share price return of 71.24 percent and a striking year to date share price return of 731.08 percent. The 1 year total shareholder return of 727.63 percent signals that momentum is still firmly building. If Palvella's rare disease surge has caught your eye, this could be a good moment to scout other specialised healthcare opportunities using our healthcare stocks as a starting point. With Palvella still loss making yet trading at a steep discount to bullish analyst targets, investors now face a crucial question: is this a rare disease champion still undervalued, or has the market already priced in its future growth? Palvella's latest close at $99.73 comes alongside a steep price to book ratio of 30.5 times, placing it well above typical biotech valuations. The price to book multiple compares a company's market value to its net assets, a common
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics (NASDAQ:PVLA) was given a new $204.00 price target on by analysts at Canaccord Genuity Group Inc..MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $97.00 to $133.00. They now have a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 12/19/25 - Form 4
- 12/17/25 - Form 144
- 12/15/25 - Form 8-K
- PVLA's page on the SEC website